NCT06814730Active, not recruitingPhase 1
A Double-Blind, Randomized, Placebo-Controlled, Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of THN391 in Early Alzheimer’s Disease Subjects
Source: EU CTIS (euclinicaltrials.eu) · Last updated 11 Aug 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 3 Jan 2025
- Start date
- 8 May 2025
- Lead sponsor
- Therini Bio Inc.
- Diseases
- Alzheimer disease
- NCT number
- NCT06814730
- EU CT number
- 2024-519899-72-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 12
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC Stichting Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Active, not recruiting |
| CTC Netherlands B.V. Coordinator of this site? Confirm its status | Groningen | Netherlands | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.